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miRNA Expression Profiling in Melanocytes and
Melanoma Cell Lines Reveals miRNAs Associated
with Formation and Progression of Malignant
Melanoma
Daniel W. Mueller1, Michael Rehli2 and Anja K. Bosserhoff1
Although deregulated expression of microRNAs (miRNAs) demonstrably contributes to the development and
progression of all types of human cancers, little data are available about the changes in miRNA expression levels
in malignant melanoma. In our study, we performed microarray-based miRNA profiling of melanocytes and
melanoma cell lines derived from either primary tumors or metastatic melanomas. In addition, we analyzed
miRNA expression patterns of melanoma cell clones in which the expression of melanoma specific genes was
stably knocked down by antisense techniques. We also generated miRNA expression profiles for two
derivatives of a melanoma cell line that differ in their invasive potential. Comparing miRNA expression patterns
of melanocytes and subsets of melanoma cell lines, we identified large cohorts of miRNAs associated with
malignant transformation as well as with the progression of the disease and with metastatic colonization.
Surprisingly, the bulk of miRNAs that deregulated most strongly was not described to be of importance in tumor
development before. The results of our study, therefore, not only provide insights into alterations in the
miRnomes of melanocytes and melanoma cell lines during melanoma progression but also present a large
assortment of miRNAs to be analyzed for their potential as diagnostic markers or targets for therapies in the
future.
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INTRODUCTION
The discovery of a new class of small non-coding RNAs—the
so-called microRNAs (miRNAs)—gave rise to a new, highly
interesting field of molecular biology. These miRNAs are
initially transcribed mainly by RNA polymerase II as capped
and polyadenylated primary transcripts, which are called pri-
miRs (Cai et al., 2004; Lee et al., 2004; Kim, 2005). After
processing of the pri-miR by a microprocessor complex
(composed predominantly of the RNAse III enzyme Drosha)
and a second RNAse III enzyme known as Dicer, an
approximately 18–24 nucleotide duplex is loaded on the
miRNA-induced silencing complex (miRISC, also called
miRNPs) (Du and Zamore, 2005; Bushati and Cohen, 2007;
Peters and Meister, 2007; Rana, 2007). Only one strand of the
duplex—the mature miRNA—remains stable on the miRISC
and induces post-transcriptional silencing of one or more
target gene(s) by binding with imperfect complementarity to a
target sequence in the 30-UTR of a target RNA with respect to
a set of general rules that are only incompletely determined
experimentally and bioinformatically to date (Doench and
Sharp, 2004; Brennecke et al., 2005; Lewis et al., 2005;
Grimson et al., 2007; Nielsen et al., 2007). miRNAs mediate
post-transcriptional silencing either by destabilization of the
target mRNA (Behm-Ansmant et al., 2006; Giraldez et al.,
2006; Wu et al., 2006) or by repression of translation (Pillai
et al., 2007; Standart and Jackson, 2007); it is not yet clear if
the latter occurs at the initiation or after the initiation step
(Filipowicz et al., 2008). To date, more than 500 miRNAs
have been discovered in the human genome, resulting in an
estimated total number of 1,000 possible miRNA genes.
Taking into consideration that every miRNA can target
several mRNAs, about 30% of genes in the human genome
could be regulated by miRNAs (Lewis et al., 2005). It is
already widely accepted that miRNAs are involved in the
regulation of multiple cellular processes, such as develop-
mental patterning, lineage differentiation, apoptosis, prolif-
eration, and antiviral defense. Owing to the participation of
miRNAs in the above-mentioned processes, it becomes clear
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that abnormalities in miRNA activity also play an important
role in the formation and progression of cancer diseases
(Esquela-Kerscher and Slack, 2006; Kloosterman and Plas-
terk, 2006; Bushati and Cohen, 2007; Chang and Mendell,
2007; Hwang and Mendell, 2007).
As a consequence of the important role of miRNAs in
cancer development, several studies comparing miRNA
expression profiles of various tumors with corresponding
normal tissues have been performed (Lu et al., 2005; Volinia
et al., 2006; Zhang et al., 2006; Gaur et al., 2007). Those
studies revealed that alterations in miRNA expression profiles
can serve as phenotypic signatures of particular types of
cancer. Thus, it becomes clear that profiling of miRNA
expression harbors a high potential to identify miRNAs that
may serve as both diagnostic markers and therapeutic targets
in many different tumor types in the future.
Although some data regarding altered miRNA expression
in malignant melanoma are included in parts of the above-
mentioned studies, there is a lack of studies comparing
normal human epidermal melanocytes (NHEMs) with estab-
lished melanoma cell lines with respect to a large number of
known miRNAs. In our study, we performed miRNA
expression arrays comparing NHEMs with melanoma cell
lines derived from primary tumors and metastases (Giard
et al., 1973; Jacob et al., 1998), as well as from different
antisense cell clones, which are used as model systems for
examining molecular changes in the malignant transforma-
tion of melanocytes into melanoma cells in our laboratory
(Poser et al., 2001, 2004; Kuphal et al., 2005; Tatzel et al.,
2005). Thus, we were able to identify sets of miRNAs with
altered expression during malignant transformation as well as
in the progression of the disease and in metastasizing events.
In addition, we found several miRNAs influenced when
genes highly important in malignant melanoma are knocked
down by antisense techniques, and we could also show that
the miRNA expression profiles of those cell lines exhibit high
similarity to the miRnome of cultured NHEMs. The results of
our study provide insights into alterations of the miRnome in
malignant melanoma cell lines and present a cohort of
miRNAs that have to be analyzed for their potential to serve
as diagnostic markers or targets for therapies in the future.
RESULTS
Comparison of miRnomes of melanocytes and melanoma cell lines
The microarray experiment included pooled NHEMs from
two donors, three melanoma cell lines derived from primary
melanomas (Mel Ei, Mel Wei, and Mel Juso), four cell lines
derived from melanoma metastases (Mel Im, Mel Ju, HMB2,
and A375), and HMB2 cell clones stably transfected with an
antisense melanoma inhibitory activity (MIA) construct
(Tatzel et al., 2005), as well as Mel Im cell clones stably
transfected with an antisense Snail (as-Snail) construct
(Kuphal et al., 2005). In addition, we analyzed two Mel Im
derivatives differing in their invasive behavior (Mel Im hi,
highly invasive; Mel Im wi, weakly invasive) (Jacob et al., 1995).
For each cell line, analysis was performed in duplicates. The
Agilent miRNA microarrays contained 470 human and 64 viral
microRNAs from the Sanger database (v 9.1).
First, an unsupervised analysis was performed using
melanocytes, the seven tested melanoma cell lines, and the
MIA-deficient HMB2 cell clone, HMB2-MIA5, to observe
whether the miRNA expression profiles reflect the origins of
the cell lines. The miRNA tree well-separated NHEMs and
HMB2-MIA5 (which clustered together) from the melanoma
cell lines (Figure 1 and Figure S1). In contrast to the origin of
the melanoma cell lines, one melanoma cluster consisted of
two metastatic cell lines (Mel Im and Mel Ju) and one primary
tumor cell line (Mel Juso). The other melanoma cluster
comprised two melanoma cell lines derived from primary
tumors (Mel Ei and Mel Wei) and one melanoma cell line
derived from a metastasis (A375). Another metastatic cell
line, HMB2, showed a somewhat distinct expression pattern,
resulting in clustering at a distance from the two other
melanoma clusters.
In addition, we performed unsupervised analysis of
melanocytes, the Mel Im cell line, and its derivatives, Mel
Im hi and Mel Im wi, together with the as-Snail cell clones to
find out if the as-Snail clones can be distinguished from the
other Mel Im cell lines with respect to their miRNA
expression profile. The resulting miRNA tree separated the
Mel Im cell line, with its derivatives differing in invasive
behavior from the melanocytes, which clustered together
with the as-Snail clones (Figure 2 and Figure S2).
Determining miRNAs related to early progression, metastasis,
and progression of malignant melanoma
To identify miRNAs deregulated in the transition of melano-
cytes into melanoma cells, we compared the expression of
461 miRNAs in melanocytes with primary melanoma cell
lines. The criterion for considering a miRNA as deregulated
was an at least three-fold up- or downregulation, in primary
melanoma cell lines compared with NHEMs. Values of
o20% of the mean fluorescence intensity of all signals and
miRNAs expressed in only one of the primary melanoma cell
lines were also excluded from the analysis. We found 91
miRNAs fulfilling our criteria, of which 77 were upregulated
(Table S1) and only 14 were downregulated (Table 1) in
primary melanoma cell lines. To narrow the list of
upregulated genes, we focused on miRNAs that were
Melanocytes HMB2-MIA5 HMB2 Mel Juso Mel Ju Mel Ei Mel Wei A375Mel lm
Figure 1. Unsupervised clustering of melanocytes and melanoma cell lines.
Schematic representation of a miRNA tree generated by the comparison of
miRNA expression profiles of melanocytes with melanoma cell lines (see text
for more information).
Mel Im Mel Im hi Mel Im wi Melanocytes As-snail
Figure 2. Unsupervised clustering of melanocytes, melanoma cell line Mel
Im, and its derivatives. Schematic representation of a miRNA tree generated
by the comparison of miRNA expression profiles of melanocytes with
derivatives of the malignant melanoma cell line Mel Im (see text for more
information).
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upregulated more than 10-fold in primary melanoma cell
lines or that were not expressed in melanocytes but highly
expressed in primary melanoma cell lines. Thus, we were
able to identify a cohort of 49 miRNAs strongly upregulated
during early progression (Table 1; for mean fluorescence
intensity of signals, see Table S1).
Next, we compared miRNA expression levels in primary
melanoma cell lines with those in melanoma cell lines
derived from metastatic melanomas to identify miRNAs
associated with metastatic colonization. In addition to the
above-mentioned criteria (three-fold up-/downregulation,
20% of mean intensity, and exclusion of miRNAs only
expressed in one of the cell lines), miRNAs considered as
deregulated in metastasis had to be expressed at the same
level in melanocytes and in primary melanoma cell lines. We
found 13 miRNAs deregulated, of which 11 were upregulated
and only 2 were downregulated in metastatic melanoma cell
lines (Table 2).
Later we wanted to identify miRNAs strongly related to the
progression of malignant melanoma, and looked for miRNAs
steadily up- or downregulated during early progression and
subsequent metastasis. We found six miRNAs upregulated at
least three-fold from melanocytes to primary melanoma and
again from primary melanoma to metastatic melanoma cell
lines (miR-133a, miR-199b, miR-453, miR-520f, miR-521,
and miR-551b), and one miRNA whose expression was
downregulated to less than one-third from melanocytes to
primary melanoma and again from primary melanoma to
metastatic melanoma cell lines (miR-190). In addition,
comparing the lists of miRNAs related to early progression
and the list of miRNAs involved in metastasis, we identified
seven miRNAs that were either upregulated during early
progression and subsequently downregulated in metastatic
colonization (miR-126, miR-29c, miR-506, miR-507, and
miR-520d*) or vice versa (miR-489 and miR-527).
Determining miRNAs deregulated in melanoma model systems
To analyze the role of the transcription factor Snail in
malignant melanoma, Mel Im cell clones were created in
which Snail expression is stably knocked down by an as-Snail
construct (Poser et al., 2001; Kuphal et al., 2004, 2005). In
this study, we analyzed the miRnome of those as-Snail cell
clones compared with cells of the parental melanoma cell
line Mel Im. We found 64 miRNAs differentially expressed in
as-Snail clones compared with Mel Im cells when setting the
cut-off to three-fold up- and downregulated. The cohort
contains 46 miRNAs upregulated and 18 miRNAs down-
regulated in the as-Snail clones (Table 3).
MIA-deficient melanoma cell clones were generated in
our laboratory by stable transfection of HMB2 melanoma
cells with an antisense-MIA cDNA expression plasmid (Poser
et al., 2004). The MIA-deficient cell clones showed a
recovery of pigmentation and a melanocytic growth pattern
(Tatzel et al., 2005). cDNA and protein array data displayed
that MIA-deficient cell clones also show high similarities in
gene expression to melanocytic cells, which enables us to use
Table 1. miRNAs found to be upregulated or
downregulated in primary tumor cell lines compared
with NHEMs and thus associated with early
progression
miRNAs upregulated during early progression
hsa-miR-10a hsa-miR-326 hsa-miR-526b
hsa-miR-126 hsa-miR-340 hsa-miR-545
hsa-miR-135b hsa-miR-373 hsa-miR-550
hsa-miR-141 hsa-miR-379 hsa-miR-557
hsa-miR-145 hsa-miR-382 hsa-miR-564
hsa-miR-181a* hsa-miR-383 hsa-miR-583
hsa-miR-182 hsa-miR-449 hsa-miR-622
hsa-miR-183 hsa-miR-454-5p hsa-miR-628
hsa-miR-18a* hsa-miR-504 hsa-miR-640
hsa-miR-196b hsa-miR-507 hsa-miR-641
hsa-miR-200a* hsa-miR-517* hsa-miR-658
hsa-miR-200c hsa-miR-518a hsa-miR-662
hsa-miR-218 hsa-miR-518f* hsa-miR-758
hsa-miR-26b hsa-miR-520b hsa-miR-9
hsa-miR-27b hsa-miR-520d hsa-miR-92b
hsa-miR-301 hsa-miR-520d*
hsa-miR-30a-3p hsa-miR-525
miRNAs downregulated during early progression
hsa-miR-148b hsa-miR-331 hsa-miR-489
hsa-miR-181a hsa-miR-363 hsa-miR-503
hsa-miR-23b hsa-miR-422b hsa-miR-527
hsa-miR-299-3p hsa-miR-455 hsa-miR-595
hsa-miR-324-5p hsa-miR-485-3p
Table 2. miRNAs found to be upregulated or
downregulated in metastatic melanoma cell lines
compared with primary tumor cell lines and thus
associated with the metastatic colonization of
malignant melanoma cells
miRNAs upregulated in metastatic cell lines
hsa-miR-199a* hsa-miR-515-3p hsa-miR-519d
hsa-miR-302c* hsa-miR-517b hsa-miR-520f
hsa-miR-30a-5p hsa-miR-518b hsa-miR-523
hsa-miR-425-3p hsa-miR-519b
miRNAs downregulated in metastatic cell lines
hsa-miR-30e-3p hsa-miR-514
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the HMB2/HMB2-MIA cell system as a model system for
investigating molecular differences between ‘‘melanocytes’’
and melanoma cells. We now also wanted to analyze the
miRnome of those cells compared with that of melanocytes.
We first compared miRNA expression of the MIA-deficient
cell clones with that of cells of the parental HMB2 cell line
and found 83 deregulated miRNAs (30 miRNAs upregulated
and 53 miRNAs downregulated in HMB2-MIA cells; Table
S2). To narrow the list of interesting miRNAs deregulated in
the MIA-deficient HMB2 cell clones, we filtered the
candidates for miRNAs 10-fold up- or downregulated, and
thus identified a cohort of 46 miRNAs (with 12 up- and 34
downregulated miRNAs; Table 4). The fact that more miRNAs
are downregulated when MIA is knocked out (about 60% of
deregulated miRNAs) fits our observation that more miRNAs
are up- than downregulated during early progression.
Comparing relative expression levels of 461 miRNAs, we
found 311 miRNAs (B70% of all miRNAs) equably
expressed in melanocytes and in MIA-deficient cell clones
HMB2-MIA (data not shown). Comparing the lists of miRNAs
deregulated during early progression (checking NHEMs
against primary tumor cell lines) and deregulated comparing
MIA-deficient HMB2 cell clones with the parental HMB2
cells revealed 18 miRNAs equably regulated (that is,
upregulated in early progression and downregulated when
MIA is knocked down or vice versa) (Table S3).
In our laboratory, we also use derivatives of Mel Im cells
called Mel Im wi and Mel Im hi (Jacob et al., 1995). These
two sublines strongly differ in their invasive behavior, with
the weakly invasive phenotype (Mel Im wi) harboring only
50% of the invasive potential of parental Mel Im cells, and
the highly invasive phenotype (Mel Im hi) showing 250% of
the invasive potential of parental Mel Im cells. By continuous
propagation in tissue culture for more than 40 passages and
repeated analyses, we were able to show that these sublines
represent genetically stable phenotypes. To identify miRNAs
having an influence on invasiveness of melanoma cells, we
compared miRNA expression levels of highly invasive Mel Im
cells (Mel Im hi) with a less-invasive Mel Im derivative (Mel
Im wi). We found 69 miRNAs to be differently expressed (34
upregulated and 35 downregulated in the more invasive
phenotype; Table 5). Comparing this cohort of miRNAs with
the lists of miRNAs deregulated in metastatic colonization
on the one hand and with the list of miRNAs deregulated in
early progression on the other, we found three (miR-133a,
Table 3. miRNAs found to be upregulated or
downregulated in as-Snail cell clones compared with
cells of the parental Mel Im cell line
miRNAs upregulated in as-Snail cell clones
hsa-miR-125b hsa-miR-206 hsa-miR-450
hsa-miR-126 hsa-miR-21 hsa-miR-506
hsa-miR-130a hsa-miR-218 hsa-miR-507
hsa-miR-143 hsa-miR-224 hsa-miR-526b
hsa-miR-148b hsa-miR-23a hsa-miR-592
hsa-miR-15b hsa-miR-23b hsa-miR-596
hsa-miR-181a* hsa-miR-26a hsa-miR-598
hsa-miR-189 hsa-miR-32 hsa-miR-606
hsa-miR-191 hsa-miR-324-5p hsa-miR-624
hsa-miR-191* hsa-miR-330 hsa-miR-641
hsa-miR-192 hsa-miR-335 hsa-miR-660
hsa-miR-194 hsa-miR-362 hsa-miR-663
hsa-miR-195 hsa-miR-378 hsa-miR-9*
hsa-miR-196a hsa-miR-425-3p hsa-miR-96
hsa-miR-199a* hsa-miR-431
hsa-miR-200a* hsa-miR-432
miRNAs downregulated in as-Snail cell clones
hsa-miR-122a hsa-miR-365 hsa-miR-489
hsa-miR-181d hsa-miR-381 hsa-miR-491
hsa-miR-196b hsa-miR-382 hsa-miR-517*
hsa-miR-299-5p hsa-miR-383 hsa-miR-539
hsa-miR-34b hsa-miR-423 hsa-miR-551b
hsa-miR-363 hsa-miR-454-5p hsa-miR-758
Table 4. miRNAs found to be upregulated or
downregulated in MIA-deficient HMB2 cell clones
HMB2-MIA compared with cells of the parental HMB2
cell line
miRNAs upregulated in HMB2-MIA cell clones
hsa-miR-10b hsa-miR-34c hsa-miR-609
hsa-miR-145 hsa-miR-485-3p hsa-miR-640
hsa-miR-224 hsa-miR-539 hsa-miR-9*
hsa-miR-335 hsa-miR-606
miRNAs downregulated in HMB2-MIA cell clones
hsa-miR-126* hsa-miR-487a hsa-miR-596
hsa-miR-141 hsa-miR-506 hsa-miR-625
hsa-miR-146a hsa-miR-507 hsa-miR-627
hsa-miR-148a hsa-miR-514 hsa-miR-632
hsa-miR-196a hsa-miR-518d hsa-miR-641
hsa-miR-203 hsa-miR-545 hsa-miR-658
hsa-miR-21 hsa-miR-550 hsa-miR-660
hsa-miR-345 hsa-miR-551b hsa-miR-767-5p
hsa-miR-373 hsa-miR-565 hsa-miR-768-3p
hsa-miR-374 hsa-miR-571 hsa-miR-769-5p
hsa-miR-449 hsa-miR-577
hsa-miR-454-3p hsa-miR-583
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miR-302c*, and miR-523) and nine equably regulated
candidate miRNAs (upregulated: miR-183, miR-200a*, miR-
362, miR-378, miR-518f*, miR-560, and miR-628; down-
regulated: miR-23b and miR-331), respectively.
Confirmation of array data by quantitative real-time PCR in
NHEMs, melanoma cell lines, and melanoma tissue samples
To ensure the quality of our data derived from the miRNA
microarray experiments, we performed a quantitative real-
time PCR (qRT-PCR) analysis on a set of seven miRNAs
comparing the expression levels in different pools of NHEMs
with three primary melanoma cell lines (Mel Ei, Mel Wei, and
Mel Juso) as well as in three metastatic cell lines (Mel Im, Mel
Ju, and A375). In addition, we included a set of melanoma
tissue samples containing four primary tumor samples and six
samples derived from melanoma metastases (lung, skin,
brain, small intestine, and two lymph-node metastases) in
our analysis to investigate whether observed changes in the
expression of some miRNAs in vitro also play a role in vivo or
whether they might be an artifact of long-term melanoma cell
lines and cell culture conditions.
A qRT-PCR analysis of miR-17-5p, miR-222, miR-181a,
miR-194, miR-22, and miR-373 expressions in melanocytes
and melanoma cell lines is in agreement with the data
obtained by the miRNA microarray experiments (Figures 3a–e
and 4a). miR-17-5p (Figure 3a) serves as an example of a
miRNA upregulated during the progression of malignant
melanoma and was chosen because it is a miRNA that is
already described in the literature in detail (see the section
Discussion). The miRNA miR-222 (Figure 3b) was detected to
be weakly upregulated during melanoma progression in the
microarray experiments but did not pass our very strict
selection criteria for identifying the most interesting miRNAs
for future analysis. The rationale for our selection criteria is
supported by qRT-PCR data obtained by the analysis of
melanoma tumor samples in which miR-222 expression also
appears only weakly deregulated, for example, in comparison
with miR-17-5p. The miRNAs miR-181a (Figure 3c) and miR-
194 (Figure 3d) were taken as examples for miRNAs
downregulated in melanoma progression. miR-181a is
already known to function as a tumor suppressor in glioma
cells triggering growth inhibition, inducing apoptosis, and
inhibiting invasion (Shi et al., 2008), whereas the only
information available for the function of miR-194 is its
involvement in intestinal epithelial cell differentiation (Hino
et al., 2008). To also examine the expression level of a
miRNA not differentially expressed between melanocytes
and melanoma cells, we further analyzed miR-22 (Figure 3e).
We were able to show that in accordance with the microarray
data, miR-22 expression was not shown to be differentially
regulated in these qRT-PCR experiments. Our data reveal that
the changes in miRNA expression levels detectable in
melanoma cell lines can also be observed in melanoma
tissue samples, although expression levels are more variable
between tissue samples and x-fold changes might be higher
or lower in tissue samples than in long-term melanoma
cell lines.
As mentioned above, we also analyzed the expression
level of miR-373 in melanocytes, melanoma cell lines, and
melanoma tissue samples. Upregulation of this miRNA in
melanoma cell lines as detected in the microarray study
was confirmed by qRT-PCR (Figure 4a). miR-373 was of
special interest for us, as it is one member of the panel of
miRNAs that we found to be equably deregulated in our
HMB2/HMB2-MIA melanoma model system during the
microarray study (see Table S3). We were able to
confirm this deregulation by qRT-PCR as shown in Figure
4b. Looking at the miR-373 expression levels in melanoma
tumor samples, we found a diverse expression pattern
reflected by the high standard deviation seen in Figure 4a.
Two of the four primary tumor samples showed strongly
induced expression of miR-373, whereas the remaining
samples showed a very low expression level. Accordingly,
three of the six melanoma metastases showed strongly
induced miR-373 expression, whereas the remaining
Table 5. miRNAs found to be upregulated or
downregulated in the highly invasive Mel Im
derivative (Mel Im hi) compared with an Mel Im
derivative with a less-invasive phenotype (Mel Im wi)
miRNAs upregulated in highly invasive Mel Im cells
hsa-miR-122a hsa-miR-21 hsa-miR-518f*
hsa-miR-132 hsa-miR-28 hsa-miR-523
hsa-miR-133a hsa-miR-302c* hsa-miR-526a
hsa-miR-133b hsa-miR-30e-3p hsa-miR-560
hsa-miR-15a hsa-miR-31 hsa-miR-628
hsa-miR-15b hsa-miR-362 hsa-miR-631
hsa-miR-17-3p hsa-miR-373* hsa-miR-659
hsa-miR-181b hsa-miR-378 hsa-miR-660
hsa-miR-183 hsa-miR-425-5p hsa-miR-662
hsa-miR-187 hsa-miR-489 hsa-miR-770-5p
hsa-miR-200a* hsa-miR-493-3p hsa-miR-99b
miRNAs downregulated in highly invasive Mel Im cells
hsa-miR-10a hsa-miR-330 hsa-miR-590
hsa-miR-134 hsa-miR-331 hsa-miR-602
hsa-miR-151 hsa-miR-34c hsa-miR-609
hsa-miR-152 hsa-miR-371 hsa-miR-625
hsa-miR-18a hsa-miR-449 hsa-miR-629
hsa-miR-18a* hsa-miR-484 hsa-miR-650
hsa-miR-191* hsa-miR-506 hsa-miR-652
hsa-miR-204 hsa-miR-509 hsa-miR-7
hsa-miR-211 hsa-miR-510 hsa-miR-766
hsa-miR-219 hsa-miR-519b hsa-miR-92b
hsa-miR-23b hsa-miR-520b
hsa-miR-296 hsa-miR-574
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metastatic tissue samples showed almost no expression of
miR-373 at all.
In the panel of seven miRNAs initially chosen for qRT-PCR
confirmation of our microarray data, we also had one
miRNA—miR-148b—whose expression was shown to be
incorrectly detected by the miRNA microarray analysis. In
contrast to the microarray data, expression of miR-148b was
detected to be upregulated in the melanoma cell lines rather
than downregulated (Figure 3f).
Analysis of the expression of a possible miRNA target gene,
Rab38, in melanocytes, melanoma cell lines, and melanoma
tissue samples
As a consequence of imperfect base pairing, which is the
mechanism by which miRNAs bind to target sequences in the
30-UTRs of their target gene transcripts, current algorithms for
miRNA/target predictions give rise to lists containing up to
several hundred possible target genes for each individual
miRNA. Searching for target genes for our sets of miRNAs
would have very likely resulted in dozens of potential ‘‘target
genes’’ presumably involved in melanoma progression and
would have been of no further help.
To get additional information about the importance of the
miRNAs that we detected to be deregulated in melanoma, we
decided to analyze the expression of the gene Rab38. Rab38
(also called ‘‘melanocyte differentiation antigen RAB38/NY-
MEL-1’’) is a member of the Rab small G-protein family that
regulates intracellular vesicle trafficking, and is involved in
the biogenesis of melanosomes resulting in a protein highly
expressed in melanocytes and downregulated in melanoma
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Figure 3. Comparison of miRNA expression levels detected by miRNA microarrays and qRT-PCR in NHEMs, melanoma cell lines, and melanoma tissue
samples. (a) The expression level of miR-17-5p in NHEMs, cell lines derived from primary tumors (PT), and metastases (Met.), and in primary and metastatic
melanoma tissue samples. (b) The expression level of miR-222 in the same samples. miR-17-5p and miR-222 were chosen as examples for miRNAs upregulated
in melanoma. (c and d) The expression levels of miR-181a and miR-194 in the same panel of samples. These miRs were chosen as examples for miRNAs
downregulated in melanoma. (e) The expression level of miR-22 in the same panel of samples. This miR was taken as an example of a not differentially expressed
miRNA. (f) The expression level of miR-148b in the set of samples described above. In contrast to the miRNA microarray experiments, expression of this miRNA
was found to be upregulated in our melanoma cell lines by qRT-PCR. *pp0.05; **pp0.01; ***pp0.001.
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cell lines (Jager et al., 2000; Osanai et al., 2005; Wasmeier
et al., 2006). In accordance with these findings, we were able
to detect reduced levels of Rab38 mRNA in melanoma cell
lines derived from primary tumors (about 50% downregula-
tion) and melanoma metastases (about 25% downregulation),
compared with normal melanocytes (Figure 5a, left-hand
bars). The downregulation of Rab38 mRNA was even
stronger in melanoma tissue samples from primary tumors
(about 80% downregulation) and melanoma metastases
(about 40% downregulation), compared with that from
NHEMs (Figure 5a, right-hand bars). Performing western
blots with an anti-RAB38 antibody we were able to confirm
reduced RAB38 expression on protein level (Figure 5b and c).
It is worth mentioning that, in contrast to the mRNA data, it
seems there is less RAB38 protein present in metastatic
melanoma cell lines and tissue samples than in cell lines and
tissue samples derived from primary melanomas—a fact that
provides an indication of Rab38 expression regulation by
miRNA-induced repression of translation.
Searching for miRNAs potentially targeting Rab38 mRNA
gave rise to a list of 21 miRNAs (search performed using
miRGen; Megraw et al., 2007). Looking at our list of miRNAs
deregulated in melanoma, 16 of these miRNAs do not appear
to be differentially regulated. Two other miRNAs, which are
predicted to target Rab38 mRNA, miR-181a and miR-194,
were found to be downregulated in melanoma during our
studies (data already confirmed by qRT-PCR; Figure 3c and
d), and are thus eliminated from the list. One of the three
residual miRNAs, miR-506, was shown to be first upregulated
from melanocytes to primary melanoma cell lines, but
subsequently downregulated from primary tumor to meta-
static melanoma cell lines. A regulation in this manner does
not fit the observation that the RAB38 protein expression is
further downregulated in metastatic melanoma cell lines and
tissue samples from melanoma metastases. Of the 21 miRNAs
predicted at the beginning of this analysis, only two remain to
be analyzed for a potential miRNA/target relationship with
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melanoma tissue samples, and in our HMB2/HMB2-MIA melanoma model
system.(a) The expression level of miR-373 in NHEMs, melanoma cell lines
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Rab38 mRNA (miR-9 and miR-141), as those miRNAs
appeared to be upregulated in cell lines derived from primary
tumors as well as in cell lines derived from metastases during
our microarray studies.
DISCUSSION
It is widely accepted that deregulated expression of miRNAs
is highly involved in the formation and progression of all
types of human cancers (Calin and Croce, 2006; Esquela-
Kerscher and Slack, 2006; Cho, 2007; Cowland et al., 2007;
Dalmay, 2008). Several studies showed that alterations in
miRNA expression profiles can serve as phenotypic signa-
tures of a particular cancer type. Lu et al. (2005) analyzed
217 mammalian miRNAs from 334 tissue samples, and
showed that the miRNA profiles reflected the developmental
lineage and the differentiation status of tumors. Volinia et al.
(2006) performed a large-scale miRnome analysis on 540
solid tumor samples, including lung, breast, stomach,
prostate, colon, and pancreatic tumors, thus identifying a
solid cancer miRNA signature composed largely of over-
expressed miRNAs. Zhang et al. (2006) analyzed 283 known
human miRNA genes in 227 human cancer tissue samples by
means of high-resolution array-based comparative genomic
hybridization, and showed that genomic loci harboring
miRNA genes are often subject to DNA copy number
alterations in ovarian cancer, breast cancer, and in melano-
ma. In addition, they gave evidence for a direct correlation
between copy number changes and the expression level of a
given miRNA. Gaur et al. (2007) examined the expression of
241 miRNAs in normal tissues, and the NCI-60 panel
comprised 60 cancer-derived cell lines and showed (1) that
the NCI-60 cell lines clustered because of their tissue origin
and (2) that the miRNA expression profiles of normal tissue
and tumor tissue showed significant differences, resulting in
the identification of miRNAs with oncogenic or tumor-
suppressing character, respectively.
Although these studies show that miRNA profiling can be
successfully employed to detect miRNAs deregulated in
cancer formation and progression and may thus be attractive
targets for future therapies, for malignant melanoma there has
been no study examining large panels of miRNAs comparing
NHEMs with established melanoma cell lines derived from
primary tumors as well as from metastatic melanomas.
Therefore, we performed a microarray analysis on NHEMs
and seven malignant melanoma cell lines, three of which
were derived from primary melanomas and four of which
were derived from metastatic melanomas, to identify cohorts
of miRNAs potentially involved in tumorigenesis, progres-
sion, and metastatic colonization of malignant melanoma.
Performing unsupervised clustering with all miRNAs
expressed at least in one cell line gave rise to a miRNA tree,
which well-separated NHEMs from melanoma cell lines. The
melanoma cell lines derived from primary tumors and
metastatic melanomas were not completely separated, but
showed a somehow ‘‘mixed’’ appearance. In recent publica-
tions, the melanoma cell lines used were characterized with
respect to their invasive potential (Jacob et al., 1995, 1998).
When examining the ability of melanoma cell lines derived
from primary tumors and those derived from metastatic
melanomas to invade membrane barriers, it was shown that
the mean invasive capacity of the metastatic cell lines was
significantly higher than that of the primary tumor cell lines.
Interestingly, it was shown that in addition to the metastatic
cell lines, some of the primary tumor cell lines were also able
to invade either collagen or matrigel matrices in some cases.
By measuring MMP (matrix metalloproteinase) and TIMP
(tissue inhibitor of metalloproteinase) levels, metastatic cell
lines showed higher MMP and lower TIMP levels compared
with primary tumor cells when considering at the average
values. However, in those experiments, not all cell lines
derived from primary tumors and metastasis behaved homo-
genously, but showed differences according to their different
properties in the invasion assays. For example, transforming
growth factor beta 2 (TGF-b2) levels were significantly higher
in supernatants of metastatic cell lines compared with those
of primary tumor cell lines as a collective. However, one
primary tumor cell line also showed a TGF-b2 level almost as
high as that of metastatic cell lines. Taken together, those
experiments showed that when collectives of cell lines
derived from primary tumors and metastasis were compared,
each group behaves as expected, but individual members of
each group show specific alterations, which make the
collectives a heterogeneous mass. We, therefore, can state
that despite the origin of the cell lines (primary tumor or
metastasis), every cell line harbors some specific properties
and this includes the possibility that some primary tumor cell
lines already hold the potential to become metastatic. This
fact might be reflected in the miRnomes of the melanoma cell
lines so that the unsupervised clustering cannot precisely
separate melanoma cell lines derived from primary tumors
from cell lines derived from metastatic melanomas, as some
intrinsic miRNA expression differences might not be related
to tumor stage at all. In addition, clustering can provide
evidence to support the cell lines chosen for the analysis, but
the aim is, of course, to determine single miRNAs or miRNA
clusters, with primary importance given to malignant
melanoma development and progression. While investigating
groups of cell lines derived from the same origin, we can
minimize the effects of individual alterations specific for a
single cell line.
In accordance with the results of Volinia et al. (2006), who
found a large portion of miRNAs upregulated in the types of
cancer they examined , the bulk of miRNAs we identified to
be deregulated in melanoma cell lines compared with
melanocytes was upregulated in the melanoma cell lines.
To narrow the list of miRNAs that could be promising
targets for future research, we compared the miRNA
expression profiles of melanoma cell clones used as model
systems for some steps in melanoma progression with the
miRNA profiles of NHEMs and melanoma cell lines.
MIA-deficient melanoma cell clones were generated in our
laboratory through stable transfection of HMB2 melanoma
cells with an antisense-MIA cDNA expression plasmid (Poser
et al., 2004). There is a chain of evidence that MIA regulates
the attachment/detachment of melanoma cells to the extra-
cellular matrix (Stoll et al., 2001; Bosserhoff et al., 2003;
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Bauer et al., 2006), and thus promotes the migratory behavior
of melanoma cells (Guba et al., 2000; Bosserhoff et al.,
2001). MIA-deficient cell clones show re-established cell–cell
contacts, a significantly reduced cell-diameter compared
with parental HMB2 cells, a switch from multinuclear to
mononuclear appearance of the cells, and re-established
dendritic cell protrusions. A recovery of pigmentation was
also observed (Tatzel et al., 2005) and additionally relates the
function of MIA to melanocytic differentiation and pigmenta-
tion. cDNA and protein array data displayed that MIA-
deficient cell clones show high similarities in gene expression
to melanocytic cells (for example, downregulation of
melanoma-specific genes MT1-MMP, t-PA, integrin b3,
SPARC, fibronectin, L1 protein, protein kinase C-a, and
MCAM). The most important effect mediated by the knock-
down of MIA is a switch from N-cadherin expression back to
E-cadherin expression in the MIA-deficient HMB2 cell
clones. This seems to revert the switch from E-cadherin to
N-cadherin expression in malignant transformation from
melanocytes to early melanoma cells, which subsequently
lose growth control mediated by keratinocytes—a very early
step in melanoma progression. We therefore think that using
the HMB2/HMB2-MIA cell system is a powerful model for
investigating molecular differences between ‘‘melanocytes’’
and early melanoma cells, although the MIA-deficient cell
clones are closer to ‘‘re-differentiated’’ melanoma cells still
containing some tumorigenic characteristics. In addition to
examining the transcriptome of MIA-deficient cell clones, we
also wanted to analyze the miRnome of those cells compared
with that of melanocytes. The MIA-deficient HMB2 cell
clones showed a miRNA profile very similar to that of NHEMs
(about 70% of all miRNAs are equably regulated in NHEMs
and HMB2-MIA), reflected in the fact that both cell lines
clustered together when an unsupervised analysis was
performed together with the melanoma cell lines. This shows
that the HMB2-MIA cell clones, in addition to other
melanocytic features, exhibit a miRnome similar to that of
melanocytes. By comparing the lists of miRNAs deregulated
in early progression and deregulated in HMB2-MIA, we were
able to identify 18 equably regulated miRNAs, which were
not associated earlier with melanoma or tumor development,
in general, and which will now be analyzed bioinformatically
and in functional tests.
Mel Im clones stably transfected with an as-Snail plasmid
clustered together with NHEMs when compared with other
Mel Im derivatives. Snail, a member of the Snail superfamily
of zinc finger transcription factors, was shown to be involved
in epithelial–mesenchymal transition. An important insight
into the invasive potential and metastasis of tumor cells came
from the discovery that increased motility and invasiveness of
cancer cells are reminiscent of the epithelial–mesenchymal
transition that occurs during embryonic development (Zhou
et al., 2004). Snail has been shown to convert otherwise
normal epithelial cells into mesenchymal cells through the
direct repression of E-cadherin expression. This phenomenon
has also been described for malignant melanoma develop-
ment by our group (Poser et al., 2001). In contrast to
melanocytes, Snail expression is induced in melanoma cells
and represses E-cadherin expression. Lost E-cadherin expres-
sion subsequently leads to a loss of control of melanocyte
proliferation mediated by keratinocytes and to acquisition of
an invasive tumor phenotype. A cDNA-array comparison of
paternal Mel Im cells with stable as-Snail clones showed
changes in the expression levels of genes involved in
epithelial–mesenchymal transition (downregulation of MMP-
2, EMMPRIN, SPARC, TIMP-1, t-PA, RhoA, Notch4,
N-cadherin, and re-induced expression of E-cadherin)
(Kuphal et al., 2005). As upregulation of Snail and subsequently
induced downregulation of E-cadherin are indisputably an
early event in melanoma formation, we think we are able to
identify some miRNAs deregulated in the early progression of
melanoma by comparing the miRnome of the as-Snail clones
with the miRnomes of primary melanoma cell lines. We were
able to identify only a small portion of miRNAs equably
regulated in NHEMs and Mel Im as-Snail compared with
primary melanoma cell lines, which is now subject to further
characterization. There is also a high probability of identifying
miRNAs whose expression is directly regulated by Snail
comparing the miRNA expression patterns of as-Snail clones
with the parental Mel Im cell line. Further studies on those
miRNAs may also contribute to the gathering of more
knowledge about the regulation of miRNA expression by
identifying a cohort of miRNAs whose expression is regulated
on a transcriptional level by binding of Snail to the promoter
sequences of those miRNAs. Taken together, although miRNAs
identified as differentially expressed after the knock down of
Snail and MIA cannot be exclusively considered as miRNAs
involved in melanoma formation and progression, performing
comparisons, including these model systems, may identify
miRNAs that seem promising for future analyses.
In addition, when comparing miRNAs differentially
regulated in a highly invasive derivative of the Mel Im cell
line (in comparison with a Mel Im derivative, which is only
weakly invasive) with miRNAs deregulated in cell lines
derived from metastatic melanomas, we found a small
number of miRNAs equably regulated, which is very likely
to be related to metastatic colonization.
Despite the growing knowledge about miRNAs, there are
few examples of miRNAs with known functions and target
genes in cancer. In our analyses, we found induced
expression of miR-373 in primary tumor cell lines and then
further upregulation (about two-fold) in metastatic melanoma
cell lines. This miRNA was earlier shown to be involved in
tumor invasion and metastasis by suppressing the oncogene-
induced p53 pathway and cooperating with oncogenic RAS
to promote cellular transformation (Voorhoeve et al., 2006;
Huang et al., 2008). Although the role of p53 in malignant
melanoma is not completely understood, several studies
showed an upregulation of the p53 protein in melanoma
progression rather than a downregulation (Li et al., 2006), as
the case would be if p53 were a target for miR-373 in
melanoma cells. Hence, it seems more likely that there are
additional targets for this miRNA in melanoma cells that are
involved in the progression of the disease and have to be
identified in subsequent studies. Another interesting fact
about miR-373 is that the analysis of melanoma tissue
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samples revealed that there are two sub-populations of
melanoma primary tumors and melanoma metastases with
regard to its expression level—one sub-population showing
strongly induced miR-373 expression and the other sub-
population showing almost no expression of miR-373.
Budhu et al. (2008) identified several miRNAs that are
potentially involved in the metastasis of hepatocellular
carcinoma. Comparing our miRNA cohort with their list,
we found two miRNAs upregulated (miR-219 and miR-185)
and one miRNA downregulated (miR-194) in malignant
melanoma. It is worth mentioning that those miRNAs were
already deregulated in primary tumor cell lines and then kept
at the same level in metastatic melanoma cell lines.
The proven oncogenic miRNA gene clusters, miR-17-92
and miR-106-363, were also included in the large cohort of
miRNAs that we found upregulated in malignant melanoma
cell lines (He et al., 2005; Landais et al., 2007). All members
of the miR-17-92 cluster, which promotes tumor progression
by cooperating with MYC and blocking apoptosis (He et al.,
2005), were shown to be upregulated in primary tumor cell
lines compared with NHEMs, although some members of the
cluster were only about two-fold upregulated, and thus were
outside our threshold of three-fold upregulation. The expres-
sion level of the miR-17-92 cluster is even higher in
metastatic cell lines, with an approximately two-fold
upregulation compared with primary melanoma cell lines.
This shows that the miR-17-92 gene cluster, in addition to
other types of cancers, is also involved in the progression of
malignant melanoma.
The miRNA gene cluster miR-106-363 shares many
similarities with the miR-17-92 cluster described above. We
could detect strong upregulation of miR-106a and miR-92, as
well as a slight upregulation of miR-19b expression in
primary tumor cell lines, with a further increasing level
(about two-fold) of those miRNAs in metastatic cell lines. The
members of the miR-106-363 cluster are thought to regulate
target genes that are involved in cell attachment, cell motility,
cell contact inhibition, and also cell proliferation, like Mylip
(myosin regulatory light chain-interacting protein) and Rbp1-
like (retinoblastoma binding protein 1 like) (Landais et al.,
2007). The members of the RBP1 family cause a profound
inhibition of cell proliferation and induced expression of a
senescence marker when overexpressed in breast cancer cells
(Binda et al., 2006).
In summary, our array experiments revealed that several
miRNAs, known to be deregulated in different types of
human cancers, may also play important roles in malignant
melanoma. Interestingly, the expression of those miRNAs of
known importance in processes such as cellular transforma-
tion and metastasizing events was often found to be only
slightly deregulated in our array experiments (often in the
range of two-fold). The corpus of miRNAs that we had
selected to be interesting for further examination was
deregulated more strongly (410-fold and regulated on the
basis of a yes/no decision), implicating that there may be
many miRNAs that might have even more dramatic effects on
tumorigenesis and metastasis in malignant melanoma than do
those miRNAs already described.
In addition, by performing an exemplary search for
miRNAs potentially regulating a melanoma-specific
gene (Rab38), we were able to give an ancillary application
for our lists of miRNAs found to be deregulated in
malignant melanoma. Although functional experiments are
necessary to clarify whether Rab38 expression is regulated
by a miRNA and (if this is the case) to identify the
particular miRNA regulating the Rab38 expression, our data
imply that the results obtained by our miRNA microarray
analyses will likely facilitate the search for miRNAs involved
in melanoma-specific gene regulation.
In summary, we were able to define large cohorts of
miRNAs associated with the early and late progression
of malignant melanoma potentially acting as oncogenes
and tumor suppressor genes. It will be a challenging
process to relate those miRNAs to their cellular function to
unravel the impact of miRNAs in the formation and
progression of malignant melanoma, and thus identify the
most promising targets for future therapies of this fatal
disease.
MATERIALS AND METHODS
Cell lines and cell culture conditions
Melanoma cell lines Mel Im (and its derivatives Mel Im hi and wi),
Mel Wei, Mel Juso, Mel Ei, Mel Ju, HMB2, and A375, have been
described in detail earlier (Jacob et al., 1995, 1998). MIA-deficient
HMB2 clone, HMB2-MIA5, and Mel Im cell lines stably transfected
with an as-Snail construct were also described in detail earlier
(Kuphal et al., 2005; Tatzel et al., 2005). For tissue culture, the cells
were maintained in DMEM supplemented with penicillin
(400Uml1), streptomycin (50mgml1), L-glutamine (300 mgml1),
and 10% fetal calf serum (Sigma, Deisenhofen, Germany) and split
1:5 every 3 days.
Human primary melanocytes (PromoCell, Heidelberg, Germany)
derived from normal skin were cultivated in a melanocyte growth
medium, M2 (PromoCell), under a humified atmosphere of 5% CO2
at 37 1C. Cells were used between passages 2–4 and not later than 2
days after trypsinization. For subcultivation or assay, cells were
detached with 0.05% of trypsin, 0.04% of EDTA in phosphate-
buffered saline. For miRNA microarray experiments, isolated total
RNAs from two different charges of melanocytes (passage 2 in each
case) were pooled.
miRNA microarrays
miRNA microarrays were performed using Agilent’s miRNA
Microarray System (Agilent, Santa Clara, CA) according to the
manufacturer’s instructions. Briefly, total RNA was isolated from cell
pellets using the one-step protocol of the mirVana miRNA Isolation
Kit (Ambion, Austin, TX). For each cell line and replicate, 100 ng of
total RNA were fluorescence-labeled with Cyanine 3-pCp, and
hybridized to oligonucleotide arrays for 24 hours at 55 1C. After
washing the microarrays in an ozone-depleted room, the array slides
were scanned and analyzed using an Agilent DNA microarray
scanner. Microarray images were processed using Feature Extraction
Software 8.5 (Agilent) according to the miRNA-v1_95_May07
protocol. As commonly used normalization methods are not
appropriate for miRNA microarrays, raw data were used for further
analysis after checking the reproducibility between replicates.
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Processed data were imported into Microsoft Office Excel 2003
for further analysis. Mean values of sets of cell lines were
compared (for example, melanocytes versus primary tumor cell
lines or primary tumor cell lines versus metastatic cell lines).
miRNAs were considered differentially regulated if at least
three-fold up- or downregulation was observed. miRNAs were
excluded from further analysis if expressed in only one cell line
of a set of cell lines. We also excluded values if the fluorescence
signal in a sample was o20% of the mean fluorescence signal
intensity in this sample. Additional criteria were applied in the
comparison of some sets of cell lines and are referred to in the
corresponding part of the Results section. Hierarchical clustering
was performed using TIGR MultiExperiment Viewer Version 4.0
(http://www.tm4.org/mev.html).
qRT-PCR on miRNAs derived from melanocytes, melanoma cell
lines, and melanoma tissue samples
Total RNA was isolated from cultured cells and from snap-frozen
melanoma tissue samples using the one-step protocol of a mirVana
miRNA Isolation Kit (Ambion), as described in detail earlier (Muller
and Bosserhoff, 2008).
miRNAs were reverse-transcribed using the RT reaction setup of a
mirVana qRT-PCR miRNA Detection Kit (Ambion), and qRT-PCR of
reverse-transcribed miRNAs was performed as described in detail
earlier (Muller and Bosserhoff, 2008).
Rab38 qRT-PCR on reverse-transcribed total RNA derived from
melanocytes, melanoma cell lines, and melanoma tissue samples
Total RNA was isolated from cultured cells and from snap-frozen
melanoma samples, as described above. For each sample, cDNA
was generated using a SuperScript II Reverse Transcriptase Kit
(Invitrogen, Groningen, The Netherlands).
qRT–PCR was performed on a Lightcycler (Roche, Mannheim,
Germany). cDNA template (1ml), 0.5 ml (20mM) of forward
(hRab38_fwd_97: 50-AACTTCTCCTCGCACTACCG-30) and reverse
(hRab38_rev_314: 50-TTCCACTTTGCCACTGCTTC-30) primer, and
10 ml of Sybr Premix Ex Taq (TaKaRa, Shiga, Japan) in a total of 20 ml
were applied to the following PCR program: 30 seconds at 95 1C
(initial denaturation); a 20 1C per second temperature transition rate
up to 95 1C for 10 seconds, 10 seconds at 61 1C, 20 seconds at 72 1C,
88 1C acquisition mode single, repeated 45 times (amplification).
b-Actin was used for normalization.
RAB38 western blot analysis with protein lysates derived from
melanocytes, melanoma cell lines, and melanoma tissue
samples
Western blot analysis was performed as described in detail before
(Tatzel et al., 2005), using the following antibodies: monoclonal
anti-b-actin Clone AC-15 (A5441, Sigma) and anti-human
RAB38 mAb Clone 7F1 (H00023682-M02, Abnova, Jhongli City,
Taiwan).
Statistical analysis
In the bar graphs, results are expressed as mean±SD (range) or
percent. Comparison between groups was made using Student’s
unpaired t-test. A P-value o0.05 was considered statistically
significant. All calculations were made using the GraphPad Prism
Software (GraphPad Software Inc., San Diego, CA).
Statement of institutional approvals
The study was approved by the local ethics committee. The study
was conducted according to the Declaration of Helsinki Principles.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
The authors thank Maja Klug, Andreas Polten, and Elmar Schilling for the
excellent technical assistance and friendly support in microarray handling
and processing.
SUPPLEMENTARY MATERIAL
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sion of malignant melanoma.
Table S2. Extended list of miRNAs up-/downregulated in MIA-deficient HMB2
cell clones (HMB2-MIA) compared with a parental HMB2 malignant
melanoma cell line.
Table S3. Intersection of miRNAs deregulated during early malignant
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Figure S1. Hierarchical clustering of miRNA expression profiles derived from
melanocytes and melanoma cell lines using TIGR MultiExperiment Viewer
Version 4.0 (http://www.tm4.org/mev.html).
Figure S2. Hierarchical clustering of miRNA expression profiles derived from
melanocytes and derivatives of malignant melanoma cell line Mel Im using
TIGR MultiExperiment Viewer Version 4.0 (http://www.tm4.org/mev.html).
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